Targeting histone deacetylases as a new strategy for graft versus host disease prevention
New research shows that the addition of the oral anti-cancer agent vorinostat to standard therapy given before, during, and after hematopoietic stem cell transplantation (HSCT) may safely reduce the incidence and severity ...
Dec 9, 2012
0
0